Revolutionary New Treatment: FDA Greenlights Genentech’s Evrysdi Tablet as First-Ever Tablet Therapy for Spinal Muscular Atrophy!
A New Milestone in Spinal Muscular Atrophy Treatment: The FDA Approves Evrysdi Tablets South San Francisco, CA – In a groundbreaking development, Genentech, a subsidiary of the Roche Group, recently announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for Evrysdi® (risdiplam) tablets. This non-invasive treatment is designed…